74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Certara Inc
Closed
SectorHealthcare
12.66 1.93
Overview
Share price change
24h
Min
12.57
Max
12.75
Income | -6.7M -2M |
|---|---|
Sales | -1.4M 105M |
P/E Sector Avg | 246.2 37.461 |
Profit margin | -1.882 |
Employees | 1,487 |
EBITDA | 29M 30M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +21.09% upside |
Next Earnings | 6 Nov 2025 |
|---|
Market Cap | 365M 2B |
|---|---|
Previous open | 10.73 |
Previous close | 12.66 |
News Sentiment
By Acuity
100%
0%
350 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Certara Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Certara Inc Forecast
Price Target
By TipRanks
21.09% upside
12 Months Forecast
Average 15.33 USD 21.09%
High 16 USD
Low 13 USD
Based on 8 Wall Street analysts offering 12 month price targets forCertara Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Certara Inc
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Live chat